Full Press Release Details
An overview video of Volition and our mission to advance the science of epigenetics.
Volition is developing and commercializing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of diseases including some cancers and diseases associated with NETosis, such as sepsis.
Find our more about Nu.Q ® – our nucleosome quantification technology.
Related Articles
• Press Releases VolitionRx Announces Collaboration with Sysmex
• Press Releases VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
VolitionRx Announces Collaboration with Sysmex
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
• Share
• Tweet
• Share on Facebook
• Share
Subscribe for Volition product updates .
Or, click here for Investor Updates and press releases .
" * " indicates required fields